You just read:

GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US

News provided by

GlaxoSmithKline plc

Dec 12, 2017, 10:55 ET